Evaluation of efficacy of intranasal oxytocin spray on children with autistic disorder

Evaluation of efficacy of intranasal oxytocin spray on children with autistic disorder - Intranasal oxytocin spray on children with autistic disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003812

Enrollment

Registered

2010-07-01

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autistic disorder

Interventions

Oxytocin is administered twice daily via intranasal spray. First, after the examinees have accustomed to the procedure of intranasal placebo spray for 1-2 weeks, doses administered are increased from

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Children who are seen in the pediatric outpatient clinic in Osaka University Hospital under the diagnosis of autism or autistic disorder.

Exclusion criteria

Exclusion criteria: 1. Boys without development of secondary sexual characteristics 2. Comorbid heart disorders 3. In cases where the attending doctors judged the participation to the study as inappropriate

Design outcomes

Primary

Measure	Time frame
Behavioral Evaluation of children by child behavior checklist(CBCL), autism diagnostic observation schedule(ADOS), childhood autism rating scale(CARS) will be performed before and 6 and 12 months after the initiation of therapy.	—

Countries

Japan

Contacts

Public ContactMasaya Tachibana

Osaka University United Graduate School of Child Development

m-tach@kokoro.med.osaka-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026